期刊文献+

血清HE4浓度测定对卵巢恶性肿瘤的诊断价值 被引量:18

Diagnostic Value of Serum HE4 in Ovarian Tumor
下载PDF
导出
摘要 目的探讨血清HE4(human epididymis gene product 4,HE4)水平测定对卵巢恶性肿瘤的诊断价值。方法通过酶联免疫法(ELISA法)分别测定64例卵巢上皮性恶性肿瘤患者、40例卵巢良性肿瘤患者以及40例健康妇女血清HE4水平,同时检测CA125的测定值。结果卵巢上皮性恶性肿瘤患者血清HE4测定值为395.2±231.29 pmol/L,卵巢良性肿瘤患者血清HE4测定值为43.86±20.87pmol/L,健康妇女血清HE4测定值为30.22±9.64 pmol/L。卵巢上皮性恶性肿瘤患者血清HE4水平与其他两组比较,差异有统计学意义(P<0.01),卵巢上皮性恶性肿瘤患者血清HE4水平明显高于其他两组。而卵巢良性肿瘤病变组和健康妇女组血清HE4水平比较,差异无统计学意义(P>0.05)。血清HE4测定值在148.8 pmol/L时诊断值最大,其特异性为97.5%,敏感度为86.4%,ROC曲线下的面积为0.975(95%CI0.970~1.000,P<0.001),FIGO分期、是否有远处转移及术后残余灶大小为卵巢恶性肿瘤患者生存的独立影响因素,HE4及CA125阳性或阴性、是否有淋巴结转移、腹水是否阳性、大网膜是否有转移不是卵巢恶性肿瘤患者生存的独立影响因素。结论血清HE4水平检测有助于卵巢恶性肿瘤诊断。 Objective To investigate the variation of HE4 concentration in human ovarian carcinoma and its clinicopathologic significance.Methods The serum concentration of HE4 and CA125 in 64 human ovarian carcinoma,40 ovarian benign tumor carried patients and 40 healthy control were detected by ELISA and electrochemistry irradiance methods respectively.Results The mean concentration of HE4 in 64 human ovarian carcinoma,benign tumor and healthy control was(395.2±231.29) pmol/L,(43.86±20.87) pmol/L,and(30.22±9.64) pmol/L respectively.The serum levels of HE4 were significantly higher(P0.01)in ovarian cancer than those in benign tumor group and healthy control.But there was no significantly difference between ovarian benign tumors and healthy control(P0.05).It would be best for diagnosis when serum concentration of HE4 was 148.8 pmol/L on ovarian carcinoma.The sensitivity and specificity of diagnosing were 86.4 %and 97.5% respectively.The HE4 assay in receiver operating characteristic-area under the curve(ROC-AUC)was 0.975(95%CI 0.970~1.0000,P0.001).There was not significant difference on serum concentration of HE4 in patients with or without lymph node metastasis,ascites and omentum metastasis.The independent factors of ovarian cancer survival was associated with the stage of FIGO,distant metastasis and post-operative residual lesion,but the serous HE4 contain was not independent factors for the prognosis of ovarian cancer.Conclusion It would be helpful to diagnose ovarian cancer on testing of serum HE4 contain.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2012年第3期312-317,共6页 Cancer Research on Prevention and Treatment
基金 广西科学与技术开发计划资助项目(桂科基2011217)
关键词 卵巢肿瘤 HE4 CA125 诊断 Ovarian carcinoma HE4 CA125 Diagnose
  • 相关文献

参考文献18

  • 1李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 2Li J,Dowdy S,Tipton T,et al.HE4 as a biomarker for ovarianand endometrial cancer management[J].Expert Revie Mol Di-agn,2009,9(6):555-566.
  • 3Kirchhoff C,Habben I,Ivell R,et al.A major human epidi dy-mis specific cDNA encodes a protein with sequence homologyto extracellular proteinase inhibitors[J].Biol Reprod,1991,45(2):350-357.
  • 4Kirchhoff C.Molecular characterization of epididymal proteins[J].Rev Reprod,1998,3(2):86-95.
  • 5Galgano MT,Hampton GM,Frierson HF Jr.Comprehensive a-nalysis of HE4 expression in normal and malignant human tis-sues[J].Mod Pathol,2006,19(6):847-853.
  • 6Moore RG,Brown AK,Miller MC,et al.The use of multiplenovel tumor biomarkers for the detection of ovarian carcinomain patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408.
  • 7Kbel M,Kalloger SE,Boyd N,et al.Ovarian carcinoma sub-types are different disease:implications for biomarker studies[J].PloS Med,2008,5(12):e232.
  • 8Berry NB,Cho YM,Harrington MA,et al.Transcriptional targe-ting in ovarian cancer cells using the human epididymis protein4 promoter[J].Gynecolo Oncol,2004,92(3):896-904.
  • 9Moore RG,McMeekin DS,Brown AK,et al.A noval multiplemarker bioassay utilizing HE4 and CA125 for the prediction ofovarian cancer in patients with a pelvic mass[J].Gynecol On-col,2009,112(1):40-46.
  • 10Kamei M,Yamashita S,Tokuishi K,et al.HE4 expression canbe associated with lymph node metastases and disease-free sur-vival in breast cancer[J].Anticancer Res,2010,30(11):4779-4783.

二级参考文献38

  • 1Bast RC Jr, Klug TL, St John E, et al. A radio ty using a monoclonal antibody to monitor the course of epithelial ovarian cancer[ J ]. N Engl J Med, 1983,309:883- 887.
  • 2Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen : a review of the literature [ J ]. Hum Reprod, 1989,4 : 1- 12.
  • 3Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA125 ,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer [J]. Br J Obstet Gynaecol, 1990,97:922-929.
  • 4Manjunath AP, Pratapkumar, Sujatha K, et al. Comparison of three risk of malignancy indices in evaluation of pelvic masses[ J]. Gynecol Oncol,2001,81:225-229.
  • 5Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [ J ]. Gynecol Oneol, 2007,108:402-408.
  • 6Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass [ J ]. Gynecol Oncol,2009 ,112 :40-46.
  • 7Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA125 levels in premonopausal and postmenopausal patients with pelvic masses:discrimination of benign from malignant diseases [ J ]. Am J Obstet Gynecol, 1998,159:341-346.
  • 8Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HFA (WFDC2) protein is a biomarker for ovarian carcinoma[ J]. Cancer Res ,2003,63:3695-3700.
  • 9Drapkin R, Horsten HH, LinY, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [ J]. Cancer Res,2005 ,65 :2162-2169.
  • 10Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HFA expression in normal and malignant human tissues [J]. Mod Pathol, 2006, 19: 847-853.

共引文献105

同被引文献184

引证文献18

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部